Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Brain Neoplasms 4 Neoplasms 3 Prostatic Neoplasms 2 Urogenital Neoplasms 1 Radiation Pneumonitis 1 Radiation Injuries 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Optic Neuritis 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Myelitis, Transverse 1 Myelitis 1 Myasthenia Gravis 1 Lung Neoplasms 1 Lung Diseases, Interstitial 1 Leukemia, Hairy Cell 1 Hematologic Neoplasms 1 Graft vs Host Disease 1 Glioma 1 Genital Neoplasms, Male 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

rozanolixizumab 8 zilucoplan 7 ravulizumab 6 fludarabine 5 efgartigimod alfa 5 Cyclophosphamide 5 telitacicept 3 Prednisone 3 inebilizumab 2 Rituximab 2 Pyridostigmine Bromide 2 tofacitinib 1 thymoglobulin 1 talquetamab 1 remibrutinib 1 prednylidene 1 iptacopan 1 eculizumab 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 Walk Test 1 Therapeutics 1 Tacrolimus 1 Steroids 1 Robotic Surgical Procedures 1 Psychodrama 1 Prednisolone 1 Plasma Exchange 1 Peripheral Blood Stem Cell Transplantation 1 Oxaloacetic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Myasthenia Gravis × Adrenal Cortex Hormones × 1 year × Clear all

NCT06342544 2026-01-21

IMCOMG

Fondation Ophtalmologique Adolphe de Rothschild

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡